ArticleMolecular therapy. Advances2026
High-titer modular retroviral vectors enabled by an antisense cassette design preventing dsRNA formation during virus production.
Article in Molecular therapy. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Retroviral vectors have demonstrated durable safety and therapeutic benefit in the context of cell and gene therapies, but achieving modular, independently controlled gene expression remains a major design challenge. Although antisense cassette architectures enable such regulation, yet they are limited by sharply reduced viral titers caused by double-stranded RNA (dsRNA) formation from convergent transcription during virus production. We developed an antisense cassette strategy that prevents dsRNA generation and preserves high titers. The design incorporates a sense-oriented intron containing an antisense polyadenylation signal into the transfer plasmid, enforcing premature termination of antisense transcription. This intron is subsequently spliced out of the packaged genomic RNA, thereby preventing inverted-promoter-driven dsRNA formation. The approach is compatible with both γ-retroviral and lentiviral vectors, supports diverse promoter combinations, and accommodates external introns as well as microRNA-based short hairpin RNAs for concurrent gene knockdown. As proof of concept, we engineered a dual-cassette vector containing an activation-inducible module paired with a constitutive transgene cassette, achieving robust modular expression alongside high titers. These findings establish a versatile platform enabling independent regulation of multiple genes in retroviral vectors and support the advancement of both basic research and therapeutic applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.